LifeWave has developed a broad base of intellectual property and know-how in a new medical imaging modality using very low energy Ultra Wide Band (UWB) radio frequency (RF) energy. We have more experience in developing clinical applications in UWB than any other organization in the world. LifeWave has a fundamental UWB signal processing patent granted by the USPTO with five other patents pending in cardiac, respiration, and fetal monitoring.
LifeWave has developed its technology under several U.S. government grants with the NIH, ONR, and U.S. Army and private funding. The government grant programs demonstrated assessment capability in CPR, cardiac and respiratory rate, and cardiac stroke volume. In addition the company has developed thru-wall assessment capability, demonstrating the ability to identify humans through masonry walls from distances of approximately fifty feet.
The LifeWave technology is based on ultra-wideband (UWB) radar technology which is ideally suited for development of miniature, low power medical monitoring systems that are safe and effective. The basic concept behind UWB RF sensing is to generate, transmit, and receive an extremely short burst of RF energy and the reflected energy is then analyzed to distinguish signals of interest and discriminate the signals from received noise.
The LifeWave UWB sensing technology is similar in functional concept to ultrasound but is based on electromagnetic, rather than sonic energy and uses different digital signal processing techniques. The LifeWave sensor emits very short duration pulses of low-level RF energy that propagates into the human body. As the energy enters the body, small amounts of the incident energy are reflected back to the device with signatures that vary with the dielectric properties and depth of tissues. The reflected energy is then evaluated using sophisticated and proprietary digital signal processing techniques to extract information on the type, location, size, and relative movement of the underlying tissues and organs.
The electromagnetic radiation that the LifeWave device emits is non-ionizing and very low power. The RF levels emitted by the LifeWave device are less than 1mW average and well below established guidelines published by ANSI/IEEE, NCRP, and the FCC. The FCC & FDA limits for the general public (most stringent limits) 0.08 W/kg continuous exposure (whole body average) and 1.6mW/gm for local spatial peak exposure. The LifeWave monitor is approximately 100X below these limits for whole body exposure and 2X below local exposure limits.
Copyright © LifeWave, Inc. All Rights Reserved. Site by McGuire Design.